Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subcutaneous Injection, Low Dose Alemtuzumab for Consolidation and Maintenance of Patients in Clinical Response After Having Achieved Partial or Complete Remission After 1st or 2nd Line Anti-Tumor Therapy for B-Cell CLL

NCT00336206 is registered in ClinicalTrials.gov with Tawam Hospital as lead sponsor.

NCT NCT00336206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subcutaneous Injection, Low Dose Alemtuzumab for Consolidation and Maintenance of Patients in Clinical Response After Having Achieved Partial or Complete Remission After 1st or 2nd Line Anti-Tumor Therapy for B-Cell CLL
Lead sponsor
Tawam Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 31, 2006
Completion date
October 31, 2009
Enrollment
60
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia